Journal article
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial
Abstract
AIMS: We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure (HF) in the RE-LY trial.
METHODS AND RESULTS: RE-LY compared two fixed and blinded doses of dabigatran (110 and 150 mg twice daily) with open-label warfarin in 18 113 patients with AF at increased risk for stroke. Among 4904 patients with HF, annual rates of stroke or systemic embolism (SE) were 1.92% for …
Authors
Ferreira J; Ezekowitz MD; Connolly SJ; Brueckmann M; Fraessdorf M; Reilly PA; Yusuf S; Wallentin L; Investigators OBOTR
Journal
European Journal of Heart Failure, Vol. 15, No. 9, pp. 1053–1061
Publisher
Wiley
Publication Date
September 2013
DOI
10.1093/eurjhf/hft111
ISSN
1388-9842